Poster Presentation NSW State Cancer Conference 2023

Revise, refine, reiterate: insights from beta testing an online paediatric oncology medicines database (ProCure) in preparation for implementation (#245)

Elijah Tyedmers 1 , Carolyn Mazariego 1 , Skye McKay 1 , Lauren Kelada 2 3 , Brittany McGill 2 3 , Rebecca Daly 2 3 , Claire Wakefield 3 , David Ziegler 4 5 , Natalie Taylor 1 , Patrick Nay 2
  1. School of Population Health, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia
  2. Discipline of Pediatrics and Child Health, School of Clinical Medicine, UNSW Medicine & Health, Sydney, NSW, Australia
  3. Behavioural Sciences Unit, Kids Cancer Centre, Sydney Children’s Hospital, Sydney, NSW, Australia
  4. Kids Cancer Centre, Sydney Children’s Hospital, Sydney, NSW, Australia
  5. School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia

Aims: ProCure is a novel web-based, interactive paediatric oncology medicines access database that aims to streamline the application process for compassionate-use cancer therapies. A beta version was codesigned with healthcare professionals (HCP) and developed to address the key barriers HCPs identified when navigating the complex access pathways.  The two main aims of this study are: (1) explore HCPs’ level of satisfaction with the beta version of ProCure, including design, usability, functionality, acceptability, appropriateness, and explore any perceived challenges to implementing ProCure into a clinical setting (2) apply beta-testing findings to refine any design or functionality features of ProCure.

Methods: HCPs including ‘end-users’ and paediatric oncology researchers were invited to participate in ProCure’s beta-testing phase lasting 8 weeks. Registered participants were encouraged to engage with, test and apply ProCure for real-time use. If there were no eligible patients during the beta testing period, HCPs were asked to use a past or hypothetical case to test the application and functionality of ProCure. Participants were asked to use the ‘Contact the Drug Access Navigator (DAN)’ function on the website to log feedback or bugs experienced in real-time, with each application use. Follow-up interviews were conducted using a mixed-methods approach to collect (1) quantitative data using the Acceptability of Intervention Measure (AIM) and Intervention Appropriateness Measure (IAM) to elicit end-user satisfaction with ProCure and (2) qualitative data using an interview schedule informed by the Consolidated Framework for Implementation Research (CFIR) to identify factors that might influence ProCure implementation, functionality and effectiveness. The AIM and IAM survey scores were analysed, qualitative interview data were coded to CFIR, and feedback logged via ‘Contact the DAN’ were reviewed in consultation with the website developer, to determine changes to be made for the release version of ProCure.

Results: Beta-testing is currently ongoing. As of June 2023, 9 paediatric oncology HCPs registered for beta-testing and have been interviewed. We aim to recruit 10 HCPs by 19 June 2023. Preliminary results indicate the majority of participants find ProCure an acceptable and appropriate resource. Challenges with the functionality of ProCure will be identified using CFIR and collated from the logged feedback.

Conclusion: Our preliminary findings indicate ProCure is perceived as an acceptable and appropriate resource to streamline compassionate application processes. Challenges and suggestions will be taken into consideration when refining ProCure’s next iteration and developing context-specific implementation strategies in preparation for its implementation within a clinical setting (pilot study sites).